Vasculitis
Vasculitis is a group of disorders characterized by inflammation of the blood vessels, which can cause the vessel walls to thicken, narrow, weaken, or scar, leading to restricted blood flow and damage to affected organs. Vasculitis can affect any type of blood vessel—arteries, veins, or capillaries—and any organ system, making it an extremely variable disease. The condition may be primary (occurring on its own) or secondary to other conditions such as infections, autoimmune diseases, or medications.
Last updated November 10, 2026
Understanding Vasculitis
Vasculitis is not one disease but a family of about twenty, grouped by the size of vessel they attack. Large-vessel forms, giant cell arteritis and Takayasu arteritis, inflame the aorta and its branches. Medium-vessel forms include polyarteritis nodosa and Kawasaki disease. Small-vessel forms are the biggest group: the ANCA-associated vasculitides (granulomatosis with polyangiitis, microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis) and immune-complex types such as IgA vasculitis and cryoglobulinemic vasculitis. Together the systemic forms are rare, roughly 20 to 50 new cases per million adults a year, but each has a typical face. Giant cell arteritis is the commonest in adults, almost never before 50 and peaking in the 70s, with about 20 cases per 100,000 people over 50 each year in populations of northern European descent. Kawasaki disease and IgA vasculitis are the commonest in children, affecting roughly 10 to 20 per 100,000 children a year. Skin-limited vasculitis after a drug or infection is far more common than any of these and usually settles on its own.
In every form the immune system treats the vessel wall as a target. In ANCA-associated disease, antibodies against proteinase 3 or myeloperoxidase in neutrophils trigger those cells to degranulate inside small vessels, producing necrotizing inflammation that in the kidney shows up as blood and protein in the urine and a rising creatinine, and in the lung as nodules or bleeding. In giant cell arteritis, activated T cells and macrophages invade the artery wall, interleukin-6 drives a systemic inflammatory response (an ESR often above 50 and a high CRP), and the thickened intima narrows the lumen until the tissue downstream starves: jaw pain on chewing, scalp tenderness, and in 15 to 20 percent of untreated cases, sudden permanent vision loss. The natural course depends entirely on the type. Untreated granulomatosis with polyangiitis killed more than 80 percent of patients within a year in the 1950s; with modern treatment five-year survival is about 75 to 85 percent, but roughly half of people relapse within five years, so the disease is better thought of as chronic and relapsing than as a single illness.
Treatment is matched to the type and to how much organ damage is threatened, and it has changed more in the past 15 years than in the previous 50. The 2021 American College of Rheumatology and Vasculitis Foundation guidelines and the 2022 EULAR recommendations set out the standard. For giant cell arteritis, high-dose prednisone (40 to 60 mg daily) is started the day the diagnosis is suspected, before the biopsy, because vision lost is not recovered; in the 251-patient GiACTA trial, adding weekly tocilizumab produced sustained remission at one year in 56 percent compared with 14 percent on a 26-week prednisone taper alone. For severe ANCA-associated vasculitis, the RAVE trial (197 patients) showed rituximab was at least as good as cyclophosphamide for inducing remission, 64 versus 53 percent at six months, and the ADVOCATE trial (331 patients) showed the complement inhibitor avacopan could replace most of the prednisone taper. The 704-patient PEXIVAS trial found plasma exchange did not reduce death or kidney failure and that a halved steroid dose was just as effective with fewer serious infections. Maintenance rituximab cuts major relapse from 29 to 5 percent over 28 months compared with azathioprine. In Kawasaki disease, intravenous immunoglobulin within 10 days of fever onset reduces coronary aneurysms from about 25 percent to under 5 percent.
No supplement, herb or diet treats vasculitis, and it is important to say that plainly because the stakes are organ damage. Where natural approaches honestly fit is in protecting the body from the treatment. Everyone on prednisone for more than three months should take calcium and vitamin D, which the ACR glucocorticoid-induced osteoporosis guideline recommends for all such patients because steroids can strip 5 to 15 percent of bone in the first year. Anyone on methotrexate should take folic acid, which cuts gastrointestinal side effects, liver enzyme rises and treatment discontinuation by half or more. Omega-3 fats have modest evidence for the cardiovascular risk that runs two to three times higher in people with vasculitis. What does not belong anywhere near this condition is anything sold to stimulate immunity: echinacea, elderberry, astragalus, high-dose zinc, beta-glucans and mushroom extracts are all pitched as immune activators, which is exactly the wrong direction for an autoimmune disease, and there are case reports of flares and of interference with immunosuppressants. Curcumin, fish oil and other anti-inflammatory supplements have no trials in vasculitis and must not delay or replace treatment.
The most common mistake is tapering or stopping treatment because you feel well. Vasculitis is quiet on steroids and loud when they go, and relapses often show first in blood tests and urine, not in symptoms, which is why guidelines ask for a urine dipstick, creatinine, CRP and blood count at every visit, typically monthly during the first year. Keep every one of those appointments and report new blood in the urine, a rising creatinine or a new cough with blood the same day. The second mistake is sitting on symptoms that are emergencies. In anyone over 50, a new headache with jaw ache on chewing, scalp tenderness or any change in vision needs same-day assessment, because starting prednisone within hours can save sight. The third is skipping infection prevention: ask for pneumococcal, influenza, COVID-19 and shingles vaccines before rituximab if possible, and about antibiotic prophylaxis against Pneumocystis while on high-dose steroids with cyclophosphamide or rituximab.
At a Glance
- Common symptoms
- Fever, fatigue, and general malaise, Unexplained weight loss, Muscle and joint pain
- Main treatments
- High-dose corticosteroids (prednisone) for initial inflammation control, Immunosuppressive agents (cyclophosphamide, azathioprine, methotrexate, mycophenolate) for remission induction and maintenance, Biologic therapies (rituximab) for ANCA-associated vasculitis
- Category
- Autoimmune · Varies by type; overall estimated at 20-50 per million per year for systemic vasculitides
- See a doctor if
- You develop unexplained fever, weight loss, and fatigue with skin rashes or joint pain
Symptoms
Causes
- Autoimmune attack on blood vessel walls (most common mechanism)
- Infections triggering immune-mediated vessel inflammation (hepatitis B, hepatitis C, HIV)
- Medications causing hypersensitivity vasculitis
- Other autoimmune diseases such as lupus, rheumatoid arthritis, or scleroderma
- The exact cause is unknown in many primary vasculitis types
Risk Factors
- Existing autoimmune disease
- Chronic hepatitis B or C infection
- Smoking (particularly for Buerger's disease)
- Age and sex vary by type (giant cell arteritis affects those over 50; Kawasaki disease affects young children)
- Certain medications or drug use (cocaine-associated vasculitis)
Diagnosis
- Blood tests including ESR, CRP, CBC, and comprehensive metabolic panel
- Autoantibody testing (ANCA, ANA, complement levels, cryoglobulins)
- Tissue biopsy of affected organs (skin, kidney, nerve, temporal artery) for histological confirmation
- Angiography (CTA, MRA, or conventional angiography) to detect vessel narrowing or aneurysms
- Urinalysis to assess kidney involvement
- Imaging studies (CT, MRI, PET scan) to evaluate organ involvement
Treatment
- High-dose corticosteroids (prednisone) for initial inflammation control
- Immunosuppressive agents (cyclophosphamide, azathioprine, methotrexate, mycophenolate) for remission induction and maintenance
- Biologic therapies (rituximab) for ANCA-associated vasculitis
- Plasma exchange (plasmapheresis) for severe or rapidly progressive disease
- Treatment of underlying infections (antivirals for hepatitis-associated vasculitis)
- Organ-specific supportive care (dialysis for kidney failure, wound care for skin ulcers)
Natural remedies for vasculitis: what the evidence says
Ranked by the strength of human evidence for vasculitis specifically. These sit alongside medical care, not in place of it.
Folic Acid
Strong evidenceMethotrexate is used for giant cell arteritis, non-severe granulomatosis with polyangiitis and Takayasu arteritis, and it depletes folate. A Cochrane review of 6 randomized trials (624 people on methotrexate) found folic acid supplementation reduced nausea and abdominal pain by 26 percent, abnormal liver enzymes by 77 percent and treatment discontinuation by 61 percent, with no loss of methotrexate benefit. Rheumatology guidelines therefore recommend it for everyone on methotrexate.
- Studied dose
- 1 mg folic acid daily, or 5 mg once weekly taken the day after methotrexate; some clinicians use folinic acid instead.
- Cautions
- Not a reason to skip the blood tests that monitor methotrexate. Folic acid can mask the anemia of vitamin B12 deficiency, so ask for a vitamin B12 level if you are over 60 or on metformin or acid suppressants.
Vitamin D
Moderate evidenceGlucocorticoids reduce calcium absorption and accelerate bone loss, with the steepest fall in the first 3 to 6 months of treatment. The 2022 ACR guideline on glucocorticoid-induced osteoporosis recommends vitamin D and calcium for every adult taking 2.5 mg or more of prednisone for 3 months or longer, based on pooled trials showing they preserve lumbar spine bone density by about 2 to 3 percent compared with no supplementation. Low vitamin D is also common in vasculitis patients at diagnosis, so a baseline level is worth checking.
- Studied dose
- 800 to 1,000 IU vitamin D3 daily, more if a blood level is below 20 ng/mL; take with calcium to a total intake of 1,000 to 1,200 mg daily from food and supplements.
- Cautions
- Vitamin D is not a substitute for a bisphosphonate when fracture risk is moderate or high, which it often is on long-term steroids. Avoid high-dose vitamin D in sarcoidosis or if calcium is already elevated, and have calcium checked if you take thiazide diuretics.
Calcium
Moderate evidencePaired with vitamin D, calcium is a guideline recommendation for anyone on long-term glucocorticoids. In the trials behind the ACR recommendation, calcium plus vitamin D prevented the loss of bone density seen in untreated patients over 1 to 2 years of steroid therapy, and the combination is the base on which bisphosphonates are added for those at higher fracture risk. Food sources count: dairy, canned fish with bones, tofu and leafy greens.
- Studied dose
- Enough supplemental calcium to bring total daily intake to 1,000 to 1,200 mg, split into doses of 500 mg or less because larger single doses are poorly absorbed.
- Cautions
- Separate calcium from levothyroxine, iron, quinolone and tetracycline antibiotics by 4 hours. Prefer dietary calcium where possible; supplemental calcium above 1,000 mg daily has been linked to kidney stones and, in some analyses, cardiovascular events.
Omega-3 Fatty Acids
Preliminary evidenceThere are no trials of fish oil in vasculitis itself. The rationale is cardiovascular: people with ANCA-associated vasculitis and giant cell arteritis have roughly two to three times the general population's rate of heart attack and stroke, driven by inflammation and steroids. In the 8,179-patient REDUCE-IT trial, 4 g daily of icosapent ethyl cut major cardiovascular events by 25 percent in people with raised triglycerides on a statin, and omega-3 intake lowers triglycerides by 20 to 30 percent. That is a reason to discuss it as part of a heart-risk plan, not as a treatment for vessel inflammation.
- Studied dose
- 1 to 2 g combined EPA and DHA daily from fish oil with meals; prescription icosapent ethyl 4 g daily where triglycerides are high.
- Cautions
- Doses above 3 g daily increase bleeding tendency and atrial fibrillation risk; tell your clinician if you take warfarin, a direct oral anticoagulant or aspirin, and stop a week before kidney biopsy or surgery.
What matters day to day
- Keep every monitoring visit and bring a urine sample: relapse in kidney vasculitis shows as blood or protein in the urine weeks before you feel anything, and guidelines call for a dipstick, creatinine and CRP at least monthly in the first year.
- Get vaccinated before immunosuppression if the timeline allows: rituximab wipes out antibody responses for at least 6 months, so ask for pneumococcal, influenza, COVID-19 and recombinant shingles vaccines beforehand, and avoid live vaccines while treated.
- Stop smoking completely: smoking roughly doubles cardiovascular events in vasculitis, worsens the vessel narrowing of Buerger's disease and giant cell arteritis, and is linked to higher relapse rates in ANCA-associated disease.
- Do 30 minutes of weight-bearing activity most days: walking, stair climbing or resistance work counters the muscle wasting and bone loss of prednisone, which can cost 5 to 15 percent of bone density in the first year.
- Have blood pressure, glucose and lipids checked every 3 months on treatment: prednisone raises all three, and over 40 percent of vasculitis patients develop hypertension or steroid-induced diabetes, both of which add to vessel damage.
- Carry a steroid alert card and never stop prednisone abruptly after more than 3 weeks: the adrenal glands shut down on treatment and a sudden stop can cause collapse, low blood pressure and low sodium.
Prevention
- No known prevention for most primary vasculitis types
- Treat underlying infections (hepatitis B, C) to prevent secondary vasculitis
- Quit smoking, particularly to prevent Buerger's disease
- Avoid known drug triggers when possible
- Regular monitoring and early treatment of flares can prevent organ damage
When to See a Doctor
- You develop unexplained fever, weight loss, and fatigue with skin rashes or joint pain
- You notice purpura (non-blanching purple spots), skin ulcers, or new numbness/weakness
- You experience vision changes, severe headaches, or scalp tenderness (urgent evaluation needed for giant cell arteritis)
Frequently Asked Questions
References
- Chung SA, Langford CA, Maz M, et al.. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis and Rheumatology (2021)
- Maz M, Chung SA, Abril A, et al.. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis and Rheumatology (2021)
- Jennette JC, Falk RJ, Bacon PA, et al.. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis and Rheumatism (2013)
- Stone JH, Merkel PA, Spiera R, et al.. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. New England Journal of Medicine (2010)
- Stone JH, Tuckwell K, Dimonaco S, et al.. Trial of tocilizumab in giant-cell arteritis. New England Journal of Medicine (2017)
- Walsh M, Merkel PA, Peh CA, et al.. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. New England Journal of Medicine (2020)
- Jayne DRW, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of ANCA-associated vasculitis. New England Journal of Medicine (2021)
- Shea B, Swinden MV, Tanjong Ghogomu E, et al.. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database of Systematic Reviews (2013)
- Humphrey MB, Russell L, Danila MI, et al.. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis and Rheumatology (2023)
- MedlinePlus, National Library of Medicine. Vasculitis (2024)View source
Related Conditions
Lab tests that relate to vasculitis
Have questions about Vasculitis?
Ask Mother Nature AI for personalized, evidence-based guidance.
Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.
Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.